ALNY vs. EXAS: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALNY and EXAS, comparing key factors like performance, valuation metrics, dividends, and financial strength.
Company Overview
ALNY’s market capitalization of 40.16 billion USD is substantially larger than EXAS’s 10.10 billion USD, indicating a significant difference in their market valuations.
EXAS carries a higher beta at 0.98, indicating it’s more sensitive to market moves, while ALNY (beta: 0.21) exhibits greater stability.
Symbol | ALNY | EXAS |
---|---|---|
Company Name | Alnylam Pharmaceuticals, Inc. | Exact Sciences Corporation |
Country | US | US |
Sector | Healthcare | Healthcare |
Industry | Biotechnology | Medical - Diagnostics & Research |
CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. | Mr. Kevin T. Conroy J.D. |
Price | 307.99 USD | 53.52 USD |
Market Cap | 40.16 billion USD | 10.10 billion USD |
Beta | 0.21 | 0.98 |
Exchange | NASDAQ | NASDAQ |
IPO Date | June 1, 2004 | February 1, 2001 |
ADR | No | No |
Performance Comparison
This chart compares the performance of ALNY and EXAS over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
This section compares the market valuation of ALNY and EXAS. Key takeaways regarding their valuation, when viewed within their industry context, are presented in the commentary that follows.
- ALNY’s Price-to-Earnings (P/E) ratio of -148.09 and EXAS’s P/E ratio of -9.80 both indicate negative earnings. For ALNY, this signifies current unprofitability, raising questions about its operational efficiency or market conditions. EXAS’s negative P/E also reflects a lack of current earnings, a key concern for its financial health and investor appeal.
- ALNY’s Forward PEG ratio of -40.17 and EXAS’s Forward PEG ratio of -9.10 are both in the negative range. For ALNY, a negative PEG ratio often stems from negative current earnings or forecasts of declining earnings, making its valuation difficult to assess relative to growth. Similarly, EXAS’s negative PEG suggests underlying issues with profitability or growth expectations, raising questions about its stock price compared to future prospects.
- ALNY’s Price-to-Book (P/B) ratio of 345.99 is very high. This often indicates that the market values the company significantly above its net asset value, usually reflecting strong profitability, valuable intangible assets (like brand or patents), or high expectations for future growth.
Symbol | ALNY | EXAS |
---|---|---|
Price-to-Earnings Ratio (P/E, TTM) | -148.09 | -9.80 |
Forward PEG Ratio (TTM) | -40.17 | -9.10 |
Price-to-Sales Ratio (P/S, TTM) | 17.10 | 3.57 |
Price-to-Book Ratio (P/B, TTM) | 345.99 | 4.17 |
EV-to-EBITDA (TTM) | -264.89 | -14.46 |
EV-to-Sales (TTM) | 17.22 | 4.34 |
Dividend Comparison
Neither ALNY nor EXAS currently pays a dividend; this often suggests they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
Symbol | ALNY | EXAS |
---|---|---|
Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section evaluates the financial strength of ALNY and EXAS. Noteworthy observations on their financial resilience, considered from an industry perspective, are detailed in the points that follow.
- ALNY’s Debt-to-Equity (D/E) ratio of 11.28 is very high. This indicates that the company is significantly financed by debt, which can amplify returns but also substantially increases its financial risk profile and vulnerability to earnings fluctuations.
- ALNY’s Interest Coverage Ratio (ICR) of -0.79 and EXAS’s ICR of -57.46 are both negative. For ALNY, a negative ICR means its operating earnings are insufficient to cover its interest expenses, a critical indicator of financial distress. EXAS’s negative ICR likewise signals severe difficulty in servicing its debt and raises concerns about its ongoing financial stability.
Symbol | ALNY | EXAS |
---|---|---|
Current Ratio (TTM) | 3.04 | 2.73 |
Quick Ratio (TTM) | 2.98 | 2.38 |
Debt-to-Equity Ratio (TTM) | 11.28 | 1.05 |
Debt-to-Asset Ratio (TTM) | 0.31 | 0.44 |
Net Debt-to-EBITDA Ratio (TTM) | -1.85 | -2.56 |
Interest Coverage Ratio (TTM) | -0.79 | -57.46 |